This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

approved Eylea biosimilars. These include the following: Yesafili (aflibercept-jbvf) Opuviz (aflibercept-yszy) Pavblu (aflibercept-ayyh) Ahzantive (aflibercept-mrbb) Enzeevu (aflibercept-abzv) ...

In 2024, the FDA approved biosimilar versions of Eylea, including the brand names Ahzantive, Enzeevu, Pavblu, Opuviz, and Yesafili. Anti-VEGF Treatments in the Pipeline In addition to injections, ...

The first biosimilars approved in the eye space were the ranibizumab biosimilars Byooviz (Samsung Bioepis and Biogen) and Cimerli (Coherus Biosciences), approved September 2021 and August 2022 ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of Regeneron's Eylea (aflibercept). Biocon ...

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). The ...

The other three — Tofidence™ and Tyenne® for Actemra® (tocilizumab) and Pavblu™ for Eylea® (aflibercept) — were the first commercially available biosimilars for their respective ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

Two additional biosimilars that reference Eylea were approved in August 2024: Sandoz’s Enzeevu (aflibercept-abzv) and Amgen’s Pavblu (aflibercept-ayyh). Pavblu has already launched, despite ongoing ...

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD). Enzeevu ...